2024
Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection
Cinco I, Napier E, Rhoades N, Davies M, Allison D, Kohama S, Bermudez L, Winthrop K, Fuss C, Spindel E, Messaoudi I. Immunological and microbial shifts in the aging rhesus macaque lung during nontuberculous mycobacterial infection. MBio 2024, 15: e00829-24. PMID: 38771046, PMCID: PMC11237422, DOI: 10.1128/mbio.00829-24.Peer-Reviewed Original ResearchConceptsNTM pulmonary diseaseIncreased disease severityNontuberculous mycobacteriaDisease severityBacterial DNAAged animalsAntigen-specific T cellsPulmonary diseaseAssociated with increased disease severityDysregulated macrophage responsePersistence of bacterial DNALack of animal modelsRhesus macaquesSingle-cell RNA sequencingNontuberculous mycobacterial infectionsImmune cell infiltrationRhesus macaque modelBacterial loadAged rhesus macaquesTesting novel therapeuticsRight caudal lobeLower respiratory microbiomeYears of ageMAH infectionMicrobial communities
2023
Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease
Siegel S, Griffith D, Philley J, Brown-Elliott B, Brunton A, Sullivan P, Fuss C, Strnad L, Wallace R, Winthrop K. Open-Label Trial of Amikacin Liposome Inhalation Suspension in Mycobacterium abscessus Lung Disease. CHEST Journal 2023, 164: 846-859. PMID: 37419144, PMCID: PMC10645596, DOI: 10.1016/j.chest.2023.05.036.Peer-Reviewed Original ResearchConceptsAmikacin liposome inhalation suspensionAmikacin resistanceCulture conversionInhalation suspensionMycobacterium abscessus lung diseasePresence of macrolide resistanceEnd pointsMicrobiological end pointsMonthly sputum culturesSputum culture conversionTreatment-refractory diseaseOpen-label protocolSecondary end pointsOpen-label trialCohort of patientsCavitary diseaseSputum culturePretreatment isolatesM abscessusOpen-labelOral antimicrobialsParenteral antibioticsCompanion therapyMacrolide resistanceMultidrug therapy
2022
Functional, transcriptional, and microbial shifts associated with healthy pulmonary aging in rhesus macaques
Rhoades N, Davies M, Lewis S, Cinco I, Kohama S, Bermudez L, Winthrop K, Fuss C, Mattison J, Spindel E, Messaoudi I. Functional, transcriptional, and microbial shifts associated with healthy pulmonary aging in rhesus macaques. Cell Reports 2022, 39: 110725. PMID: 35443183, PMCID: PMC9096119, DOI: 10.1016/j.celrep.2022.110725.Peer-Reviewed Original ResearchConceptsT cellsCD8<sup>+</sup> T cellsCD8<sup>+</sup> TRhesus macaque modelPulmonary function testsSevere respiratory infectionsSeverity of respiratory diseasePulmonary ageCross-sectional studyMacaque modelInfiltrating macrophagesImmunological landscapeRespiratory infectionsImpact of ageComprehensive cross-sectional studyIncreased riskAge-related changesFunction testsAged animalsIncreased prevalenceHealthy humansRespiratory tractRhesus macaquesConsequence of agingLung
2021
Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States
Ku J, Siegel S, Philley J, Schipper P, Thanawala R, Hendrick M, Sigler C, Strnad L, McShane P, Griffith D, Tieu B, Caccitolo J, Fuss C, Le A, Winthrop K. Outcomes of Resectional Thoracic Surgery for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease in 105 Patients in the United States. CHEST Journal 2021, 161: 365-369. PMID: 34390707, DOI: 10.1016/j.chest.2021.08.004.Peer-Reviewed Original ResearchExceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer
Li A, Goodyear S, Fuss C, Mitri Z. Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. JCO Precision Oncology 2021, 5: 904-909. PMID: 34994619, DOI: 10.1200/po.20.00361.Peer-Reviewed Original Research